• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Publishes Agenda for 2023 Annual General Meeting

    3/29/23 5:59:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • Alcon welcomes its shareholders to its first in-person AGM
    • In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform
    • Proposed dividend of CHF 0.21 cash per share

    Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 5, 2023.

    Alcon is pleased to welcome shareholders to its first in-person AGM since becoming an independent, standalone company in April 2019. The company looks forward to hearing directly from its shareholders at this open format meeting.

    The agenda for this 2023 AGM consists of the regular items as required by law, as well as the proposal to amend Alcon's Articles of Incorporation, in line with the entry into force of the Swiss corporate law reform and governance best practices. Alcon Board of Directors proposes in particular the introduction of a capital range and a conditional share capital to support Alcon's capital structure management in today's fast paced capital market environment. No approval is sought for future virtual AGMs.

    The invitation to the AGM, including explanatory information on individual agenda items, will be published in the Swiss Gazette of Commerce on March 30, 2023, and will be available, together with the Say-on-Pay brochure, the brochure regarding the Amendments to the Articles of Incorporation and additional related material, online at https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2023/2023-Annual-General-Meeting/default.aspx.

    Agenda for Alcon's 2023 AGM

    1.

    Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2022

     
    2.

    Discharge of the members of the Board of Directors and the members of the Executive Committee

     
    3.

    Appropriation of earnings and declaration of dividend as per the balance sheet of Alcon Inc. of December 31, 2022

     
    • If approved by the shareholders, a dividend of CHF 0.21 in cash per share will be payable with the first trading day ex-dividend expected to be May 10, 2023, the record date expected to be May 11, 2023, and the payout date in Switzerland expected to be on or around May 12, 2023. The Swiss withholding tax of 35% will be deducted from the gross dividend amount.
    4.

    Votes on the compensation of the Board of Directors and of the Executive Committee

    4.1

    Consultative vote on the 2022 Compensation Report

    4.2

    Binding vote on the maximum aggregate amount of compensation of the Board of Directors for the next term of office, i.e., from the 2023 Annual General Meeting to the

    2024 Annual General Meeting

    4.3

    Binding vote on the maximum aggregate amount of compensation of the Executive Committee for the following financial year, i.e., 2024

     
    5. Re-election of the current Chair and the current Members of the Board of Directors
     
    6. Re-election of the current members of the Compensation Committee
     
    7. Re-election of the independent representative
     
    8. Re-election of the statutory auditors
     
    9. Amendments to the Articles of Incorporation
     
    9.1 Deletion of the current Article 4a and introduction of a capital range (new Article 4a)
    9.2 Introduction of a conditional share capital (new Article 4b)
    9.3 Share capital (Article 4 and new Article 4c)
    9.4 Shareholders matters (Article 9, Article 10 paragraph 2, Article 11 paragraph 1, Article 12, Article 17, Article 18 and Article 38)
    9.5 Board of Directors and related topics (Article 22 and Article 24 paragraph 1)
    9.6 Compensation and related topics (Article 29 paragraph 4, Article 30, Article 33 and Article 34 paragraph 3 and paragraph 4)

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. An example of a forward-looking statement includes, among others, statements Alcon makes regarding the payment of a dividend.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

    Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005872/en/

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    1/30/2026Mkt Perform
    William Blair
    1/20/2026Hold → Buy
    Deutsche Bank
    1/9/2026Buy → Hold
    Stifel
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    More analyst ratings

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    1/6/26 8:19:06 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DFAN14A filed by Alcon Inc.

    DFAN14A - ALCON INC (0001167379) (Filed by)

    12/9/25 8:56:17 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    11/12/25 6:18:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Deutsche Bank

    Deutsche Bank upgraded Alcon from Hold to Buy

    1/20/26 8:36:02 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Stifel

    Stifel downgraded Alcon from Buy to Hold

    1/9/26 8:47:33 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon Launches TOTAL30 Multifocal for Astigmatism, the World's Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology

    Provides excellent end of day comfort even on day 30,^ helping patients stay in contact lenses† comfortably1 Designed for aging eyes, the Water Gradient Material offers 3x greater surface lubricity* and at least 5x softer lens surface2-3** Commercially available for Eye Care Professionals in the U.S. to meet the evolving visual needs of astigmatic presbyopes Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of TOTAL30® Multifocal for Astigmatism, the world's only multifocal toric contact lens with Water Gradient Technology, helping patients stay in lenses comfortably,† as their vision changes from stand

    2/17/26 8:03:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

    PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 Now available in Canada, PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for 16 hours of outstanding comfort and affordability when a daily disposable lens is not an option1,3 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 h

    2/2/26 9:02:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Completes $750 Million Share Repurchase Program

    Alcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate, 9,301,877 registered shares were acquired on the SIX Swiss Exchange, representing 1.9% of the current share capital of Alcon Inc. The total buyback volume amounted to CHF 602 million (USD 750 million). The registered shares acquired will be held in treasury and are intended to offset the dilutive effect of registered shares vesting under Alcon's equity-based incentive plans. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage span

    1/20/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Financials

    Live finance-specific insights

    View All

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care